From the Bothrops Jararaca Bradykinin Potentiating Peptides to Angiotensin Converting Enzyme Inhibitors

Chapter

Abstract

When Rocha e Silva received the first samples of synthetic bradykinin from Boissonnas et al. (1960), was found that it was much less potent than “natural” bradykinin made by incubation of plasma with the Bothrops jararaca venom. Erdös and Sloane (1962) demonstrated that the major inactivating enzyme in plasma had the characteristics of pancreatic carboxypeptidase B. This enzyme was a zinc metal-enzyme (Vallee, 1961). This knowledge prompted us to investigate the bradykinin potentiating activity of several metal chelating agents. BAL (dimercaptopropanol) inhibited bradykinin inactivation by plasma, and potentiated its actions “in vitro” and “in vivo” (Ferreira and Rocha e Silva, 1962, 1963; Ferreira et al., 1962; Rocha e Silva, 1963). This venom when added to an isolated guinea pig ileum preparation causes tachyphylactic contractions. Investigating if BAL could potentiate those contractions, we observed that the venom itself had a powerful peptidic potentiating substance, which we named bradykinin potentiating peptide, BPF. As the enzyme that inactivates bradykinin also converts angiotensin in the hypertensive active peptide the structure of BPF was instrumental for the development of the new synthetic family of antihypertensive drugs, named Angiotensin Converting Enzyme Inhibitors.

Keywords

Angiotensin Converting Enzyme Inhibitor Renin Inhibitor Angiotensin Receptor Antagonist Bradykinin Antagonist Oral Antihypertensive Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bakhle, Y.S., 1968. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 220, 919–921.PubMedCrossRefGoogle Scholar
  2. Bakhle, Y.S., Reynard, A.M., Vane, J.R., 1969. Metabolism of the angiotensins in isolated perfused tissues. Nature 222, 956–959.PubMedCrossRefGoogle Scholar
  3. Boissonnas, R.A., Guttmann, S., Jaquenoud, P.A., Konzett, H., Stuermer, E., 1960. Synthesis and biological activity of peptides related to bradykinin. Experientia 16, 326.PubMedCrossRefGoogle Scholar
  4. Byers, L.D., Wolfenden, R., 1972. A potent reversible inhibitor of carboxypeptidase A. J. Biol. Chem. 247, 606–608.PubMedGoogle Scholar
  5. Cushman, D.W., Cheung, H.S., Sabo, E.F., Ondetti,M.A., 1977. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16, 5484–5491.Google Scholar
  6. Erdos, E.G., 1966. Hypotensive peptides: bradykinin, kallidin, and eledoisin. Adv. Pharmacol. 4, 1–90.PubMedCrossRefGoogle Scholar
  7. Erdos, E.G., Sloane, E.M., 1962. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11, 585–592.PubMedCrossRefGoogle Scholar
  8. Ferreira, S.H., 1965. A Bradykinin-potentiation factor (BPF) present in the venom of Bothrops Jararaca. Br. J. Pharmacol. 24, 163–169.Google Scholar
  9. Ferreira, S.H., 1966. Bradykinin-potentiating factor, in: Erdos, E.G. (Ed.), Hypotensive Peptides. Springer Verlag, New York, pp. 356–367.CrossRefGoogle Scholar
  10. Ferreira, S.H., Bartelt, D.C., Greene, L.J., 1970a. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9, 2583–2593.PubMedCrossRefGoogle Scholar
  11. Ferreira, S.H., Corrado, A.P., Rocha e Silva, M., 1962. Potenciação do efeito hipotensor da bradicinina por inibição da enzima bradicininolitica plasmática. Ciências e Cultura 14, 238.Google Scholar
  12. Ferreira, S.H., Greene, L.H., Alabaster, V.A., Bakhle, Y.S., Vane, J.R., 1970b. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 225, 379–380.PubMedCrossRefGoogle Scholar
  13. Ferreira, S.H., Rocha e Silva, M., 1962. Potentiation of bradykinin by dimercaptopropanol (BAL) and other inhibitors of its destroying enzyme in plasma. Biochem. Pharmacol. 11, 1123–1128.PubMedCrossRefGoogle Scholar
  14. Ferreira, S.H., Rocha e Silva, M., 1963. Potenciação de polipeptideos por um fator presente no veneno de Bothrops jararaca. Ciências e Cultura 15, 276.Google Scholar
  15. Ferreira, S.H., Vane, J.R., 1967a. Half-lives of peptides and amines in the circulation. Nature 215, 1237–1240.PubMedCrossRefGoogle Scholar
  16. Ferreira, S.H., Vane, J.R., 1967b. The detection and estimation of bradykinin in the circulating blood. Br. J. Pharmacol. 29, 367–377.Google Scholar
  17. Gainer, J.V., Morrow, J.D., Loveland, A., King, D.J., Brown, N.J., 1998. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339, 1285–1292.PubMedCrossRefGoogle Scholar
  18. Gavras, H., Brunner, H.R., Laragh, J.H., Sealey, J.E., Gavras, I., Vukovich, R.A., 1974. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N. Engl. J. Med. 291, 817–821.PubMedCrossRefGoogle Scholar
  19. Greene, L.J., Stewart, J.M., Ferreira, S.H., 1970. Bradykinin-potentiating peptides from the venom of Bothrophs jararaca, in: Sicuteri, M., Rocha e Silva, M., Back, N. (Eds.), Bradykinin and Related Kinins: Cardiovascular, Biochemical and Neural Actions. Plenum Press, New York, pp. 81–87.CrossRefGoogle Scholar
  20. Krieger, E.M., Salgado, H.C., Assan, C.J., Greene, L.J., Ferreira, S.H., 1971. Potential screening test for detection of overactivity of renin-angiotensin system. Lancet 1, 269–271.PubMedCrossRefGoogle Scholar
  21. Martorana, P.A., Linz, W., Scholkens, B.A., 1991. Does bradykinin play a role in the cardiac antiischemic effect of the ACE-inhibitors? Basic Res. Cardiol. 86, 293–296.Google Scholar
  22. Ng, K.K., Vane, J.R., 1968. Fate of angiotensin I in the circulation. Nature 218, 144–150.PubMedCrossRefGoogle Scholar
  23. Ondetti, M.A., Williams, N.J., Sabo, E.F., Pluscec, J., Weaver, E.R., Kocy, O., 1971. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 10, 4033–4039.PubMedCrossRefGoogle Scholar
  24. Rocha e Silva, M., 1963. The physiological significance of bradykinin. Ann. N.Y. Acad. Sci. 104, 190–211.CrossRefGoogle Scholar
  25. Rocha e Silva, M., Beraldo, W.T., Rosenfeld, G., 1949. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am. J. Physiol 156, 261–273.PubMedGoogle Scholar
  26. Rosenthal, T., Kissin, E., Jacob, E.T., Stern, N., Levi, Y., Adar, R., 1979. Angiotensin-converting enzyme inhibitor (SQ 20881) in the diagnosis of renovascular hypertension. Angiology 30, 123–128.PubMedCrossRefGoogle Scholar
  27. Vallee, B.L., 1961. The “active catalytic site,” an approach through metalloenzymes. Fed. Proc. 20, 71–80.PubMedGoogle Scholar
  28. Yang, H.Y., Erdos, E.G., Levin, Y., 1971. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J. Pharmacol. Exp. Ther. 177, 291–300.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of São PauloRibeirão PretoBrazil

Personalised recommendations